Tolvaptan Sodium Phosphate

托伐普坦磷酸钠

Report date: 2025/11/20 15:20:17
NME

Base Information

Drug NameTolvaptan Sodium Phosphate
Drug Alias NameSamtasu苏麦达
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsHeart Failure
Approved Indications in ChinaHeart Failure
Original Approved Country/TerritoryJapan
Original Approved Date2022/03/28
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active IndicationsHeart Failure
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A